In this Between The Dose bonus episode of The Elevated Dose, I break down the new World Health Organization (WHO) guidelines on GLP-1 medications for obesity and what they mean for people actively using or considering GLP-1 therapy.

This episode explains, in plain language, how the WHO now formally recognizes obesity as a chronic, relapsing disease and endorses GLP-1 receptor agonists as legitimate long-term medical treatment for obesity, not shortcuts or failures of willpower.

We cover:

• ​ What the WHO guidelines actually say about GLP-1 medications for obesity
• ​ Why obesity is now classified as a chronic disease requiring ongoing care
• ​ How GLP-1 drugs like semaglutide and tirzepatide fit into long-term obesity treatment
• ​ Why weight regain after stopping GLP-1 medication is expected biology, not personal failure
• ​ The role of structure, routine, and behavioral support alongside GLP-1 therapy
• ​ The real barriers to GLP-1 access, including cost, insurance, and health-system limitations
• ​ What these guidelines mean for plateaus, slow progress, maintenance, and medication changes

This episode is especially relevant if you are:

• ​ On a GLP-1 and feeling stalled or discouraged
• ​ Navigating maintenance or worried about weight regain
• ​ Considering starting a GLP-1 medication for obesity
• ​ Recovering from years of dieting, medical gaslighting, or shame-based weight loss care

The WHO guidance validates what many people on GLP-1s already know from lived experience: obesity treatment is not about willpower; it’s about biology, access, and sustained medical support.

This episode is educational and based on lived experience. It is not medical advice. Always consult your healthcare provider regarding GLP-1 medications and obesity treatment.

Stay up to date on all things The Elevated Dose at www.theelevateddose.com

What happens after the weight loss works?

In this episode I dive into the part of GLP-1 care no one really prepares you for, the long game. The quiet exhaustion that can show up after success. The identity shift that happens when the urgency fades. And the emotional weight of realizing this isn’t a phase, a reset, or a short-term solution.

This conversation isn’t about side effects or starting a GLP-1. It’s about what comes next.

If you’ve been on a GLP-1 long enough for the excitement to wear off and you’re feeling tired even though things are “working”, this episode will help you understand why.

In this episode, we talk about:

• ​What journey fatigue really is (and what it isn’t)
• ​Why exhaustion often shows up after success
• ​The emotional reality of long-term GLP-1 care
• ​Maintenance anxiety and the fear of “messing it up”
• ​Identity shifts after weight loss
• ​Why gratitude and exhaustion can coexist
• ​Letting go of urgency and learning to live inside stability
• ​Why this isn’t a phase it’s care

Resources & Support

• ​Explore GLP-1 care and long-term provider support with Fridays: https://www.joinfridays.com/?via=carrie

Use code DOSE to save on your first month.

Stay Connected

Follow The Elevated Dose for grounded conversations about metabolic health, GLP-1 care, maintenance, and life beyond the scale.

Subscribe and leave a review if this episode resonated, it helps more people quietly navigating this phase find the show.

Share this episode with someone who did everything right… and is still tired.

Follow for more across social media at www.theelevateddose.com

This isn’t a phase.

It’s the long game.

Hi, I’m Carrie and welcome back to The Elevated Dose Podcast.

This week’s episode is one of the most personal I’ve ever recorded. It’s the story of what happens after the breakthrough; when the medication works, the numbers normalize, and yet your body still whispers that something isn’t finished.

I pick up right where Episode 1 left off, June 2022 the day I took my very first Ozempic injection thinking, this might finally be it. What follows is three years of trying, failing, healing, and learning what “better” really means.

For me, The Shift isn’t just about weight loss. It’s about what happens when you finally reach the goal you dreamed of and realize there’s still more to uncover underneath.

In this episode, I talk about:

• My full year on Ozempic at 0.25–0.5 mg

• The Trulicity year that came after

• The June 2024 switch to Mounjaro

• The August 2024 MASH diagnosis

• The September 2025 fibromyalgia diagnosis

This episode is raw and honest because as much as GLP-1s changed my life, they didn’t fix everything.

And learning to accept that truth has been its own form of healing.

🩺 A quick reminder: I’m not a doctor, this podcast is for educational purposes only, not medical advice. Always consult your healthcare provider before starting or changing any medication.

💻 Mentioned in this episode: 🩺 Fridays the telehealth that can help you access compounded GLP-1s affordably and judgment-free. Use code CARRIE for a savings on your first month.

In Episode 1: The Breaking Point, I share my decades-long struggle with weight, health, and the medical system. From my first diet at 12 to a heart attack and triple bypass at 28, a Type 2 diabetes diagnosis at 35, and a 75-pound Weight Watchers 'success' that unraveled during the pandemic, this episode tells it all. It ends in June 2022, when I took first Ozempic shot and chose hope again.

If this resonates, hit subscribe and leave a quick review so more people can find the show.

To follow me on all platforms visit: https://beacons.ai/theelevateddoseAnd if you’re curious about starting your own GLP-1 journey, visit joinfridays.com and use code CARRIE.

This episode contains affiliate links. As an affiliate I may earn a commission if you sign up using my code.